Abilify Mycite | Aripiprazole Tablet while Breastfeeding
Most health expert recommend six month of exclusive breastfeeding but statics suggest that numbers are not good, almost 95% mothers start breastfeeding but this number drops to 40% in first three month and further it drops to 15% till fifth month. Sometime its due to need of medication usage. Because of these statics its important to provide good information on safety of drugs in breastfeeding so that it can be improved when possible. In this FAQ sheet we will discuss about exposure to Abilify Mycite | Aripiprazole Tablet while breastfeeding. We will also discuss about common side effects and warnings associated with Abilify Mycite | Aripiprazole Tablet.

What is Abilify Mycite | Aripiprazole Tablet used for?


ABILIFY MYCITE, a drug-device combination product comprised of aripiprazole tablets embedded with an Ingestible Event Marker (IEM) sensor intended to track drug ingestion, is indicated for the: Treatment of adults with schizophrenia [see Clinical Studies (14.1)] Treatment of bipolar I disorder Acute treatment of adults with manic and mixed episodes as monotherapy and as adjunct to lithium or valproate [see Clinical Studies (14.2)] Maintenance treatment of adults as monotherapy and as adjunct to lithium or valproate [see Clinical Studies (14.2)] Adjunctive treatment of adults with Major Depressive Disorder [see Clinical Studies (14.3)] ABILIFY MYCITE, a drug-device combination product comprised of aripiprazole tablets embedded with an Ingestible Event Marker (IEM) sensor intended to track drug ingestion, is indicated for the: Treatment of adults with schizophrenia ( 1) Treatment of bipolar I disorder ( 1) Acute treatment of adults with manic and mixed episodes as monotherapy and as adjunct to lithium or valproate Maintenance treatment of adults as monotherapy and as adjunct to lithium or valproate Adjunctive treatment of adults with major depressive disorder (MDD) ( 1) Limitations of Use: The ability of ABILIFY MYCITE to improve patient compliance or modify aripiprazole dosage has not been established. ( 1) The use of ABILIFY MYCITE to track drug ingestion in "real-time" or during an emergency is not recommended because detection may be delayed or not occur. ( 1) Limitations of Use: The ability of the ABILIFY MYCITE to improve patient compliance or modify aripiprazole dosage has not been established [see Dosage and Administration (2.1)] . The use of ABILIFY MYCITE to track drug ingestion in "real-time" or during an emergency is not recommended because detection may be delayed or not occur [see Dosage and Administration (2.1)] .

Abilify Mycite | Aripiprazole Tablet while breastfeeding safe or not? Can there be any side effects for infant while using it during breastfeeding?

Abilify Mycite | Aripiprazole Tablet low risk for breastfeeding
Aripiprazole is the one and only active ingredient present in Abilify Mycite | Aripiprazole Tablet. Aripiprazole in itself is a low risk drug for lactation so it is easy to understand that Abilify Mycite | Aripiprazole Tablet also comes in category of Low Risk item while breastfeeding. Below is the summary of Aripiprazole in breastfeeding.

Abilify Mycite | Aripiprazole Tablet Breastfeeding Analsys


Aripiprazole while Breastfeeding

Low Risk

CAS Number: 129722-12-9

ts pharmacokinetic data (low oral bioavailability, large volume of distribution, moderately elevated molecular weight and high plasma protein binding) explains the negligible or zero passage into milk observed (Grover 2015, Nordeng 2014, Watanabe 2011, Lutz 2010, Schlotterbeck 2007). No problems were observed in infants whose mothers were taking it (Nordeng 2014, Tarikh 2014, Lutz 2010). The plasma levels of these infants were undetectable or very low (Watanabe 2011). Its relationship with prolactin is controversial because it lowers prolactin levels and has been used to treat prolactinomas and hyperprolactinemia induced by the use of other antipsychotics (Bakker 2016, Ranjbar 2015, Raghuthaman 2015, Safer 2013, Byerly 2009, Lorenz 2007, Goodnick 2002), but cases of decreased milk production have been reported (Frew 2015, Mendhekar 2006) and hyperprolactinemia triggered by aripiprazole has been reported (Sogawa 2016, Prost 2016, Saraf 2014, Mendhekar 2005, Ruffatti 2005). Due to its slow elimination, it may be worthwhile using other compatible antipsychotics with a shorter half-life, especially during the neonatal period and in case of prematurity (Uguz 2016). Monitor for possible drowsiness in the infant (Hale 2017 p.74).

Abilify Mycite | Aripiprazole Tablet Breastfeeding Analsys - 2


Aripiprazole while Breastfeeding

CAS Number: 129722-12-9

Limited information indicates that maternal doses of aripiprazole up to 15 mg daily produce low levels in milk, but until more data become available, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.[1] Aripiprazole can lower serum prolactin in a dose-related manner, but cases of gynecomastia and galactorrhea have also been reported.

Abilify Mycite | Aripiprazole Tablet and breastfeeding

What should I do if already breastfed my kid after using Abilify Mycite | Aripiprazole Tablet?

Abilify Mycite | Aripiprazole Tablet is in the category of low risk, if you have already used it then its not a big deal if health and behavior of baby is good. However your health care provider shall be aware of the fact that you have used Abilify Mycite | Aripiprazole Tablet so you should inform him based on your convenience.


I am nursing mother and my doctor has suggested me to use Abilify Mycite | Aripiprazole Tablet, is it safe?

Abilify Mycite | Aripiprazole Tablet comes in category of low risk and if your doctor is aware that you are breastfeeding it should be ok to use without much concerns.


If I am using Abilify Mycite | Aripiprazole Tablet, will my baby need extra monitoring?

Not much monitoring required while using Abilify Mycite | Aripiprazole Tablet


Who can I talk to if I have questions about usage of Abilify Mycite | Aripiprazole Tablet in breastfeeding?

US
National Womens Health and Breastfeeding Helpline: 800-994-9662 (TDD 888-220-5446) 9 a.m. and 6 p.m. ET, Monday through Friday

UK
National Breastfeeding Helpline: 0300-100-0212 9.30am to 9.30pm, daily
Association of Breastfeeding Mothers: 0300-330-5453
La Leche League: 0345-120-2918
The Breastfeeding Network supporter line in Bengali and Sylheti: 0300-456-2421
National Childbirth Trust (NCT): 0300-330-0700

Australia
National Breastfeeding Helpline: 1800-686-268 24 hours a day, 7 days a week

Canada
Telehealth Ontario for breastfeeding: 1-866-797-0000 24 hours a day, 7 days a week